Pathway-centric analysis of the DNA damage response to chemotherapeutic agents in two breast cell lines

Khanna, 2001, DNA double-strand breaks: signaling, repair and the cancer connection, Nat. Genet., 27, 247, 10.1038/85798 Thompson, 2001, Homologous recombinational repair of DNA ensures mammalian chromosome stability, Mutat. Res., 477, 131, 10.1016/S0027-5107(01)00115-4 Jackson, 2009, The DNA-damage response in human biology and disease, Nature, 461, 1071, 10.1038/nature08467 Lieber, 2010, The mechanism of double-strand DNA break repair by the nonhomologous DNA end-joining pathway, Annu. Rev. Biochem., 79, 181, 10.1146/annurev.biochem.052308.093131 Mao, 2008, DNA repair by nonhomologous end joining and homologous recombination during cell cycle in human cells, Cell Cycle, 7, 2902, 10.4161/cc.7.18.6679 Sancar, 2004, Molecular mechanisms of mammalian DNA repair and the DNA damage checkpoints, Annu. Rev. Biochem., 73, 39, 10.1146/annurev.biochem.73.011303.073723 Hanahan, 2011, Hallmarks of cancer: the next generation, Cell, 144, 646, 10.1016/j.cell.2011.02.013 Andressoo, 2005, Nucleotide excision repair and its connection with cancer and ageing, Adv. Exp. Med. Biol., 570, 45, 10.1007/1-4020-3764-3_3 Curtin, 2012, DNA repair dysregulation from cancer driver to therapeutic target, Nat. Rev. Cancer, 12, 801, 10.1038/nrc3399 Lord, 2012, The DNA damage response and cancer therapy, Nature, 481, 287, 10.1038/nature10760 Usanova, 2010, Cisplatin sensitivity of testis tumour cells is due to deficiency in interstrand-crosslink repair and low ERCC1-XPF expression, Mol. Cancer, 9, 248, 10.1186/1476-4598-9-248 Guo, 2011, DNA repair and synthetic lethality, Int. J. Oral Sci., 3, 176, 10.4248/IJOS11064 Bryant, 2005, Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase, Nature, 434, 913, 10.1038/nature03443 Farmer, 2005, Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy, Nature, 434, 917, 10.1038/nature03445 Fong, 2009, Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers, N. Engl. J. Med., 361, 123, 10.1056/NEJMoa0900212 Fong, 2010, Poly(ADP)-ribose polymerase inhibition: frequent durable responses in BRCA carrier ovarian cancer correlating with platinum-free interval, J. Clin. Oncol., 28, 2512, 10.1200/JCO.2009.26.9589 Fauzee, 2010, PARP and PARG inhibitors – new therapeutic targets in cancer treatment, Pathol. Oncol. Res., 16, 469, 10.1007/s12253-010-9266-6 Gewirtz, 1999, A critical evaluation of the mechanisms of action proposed for the antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin, Biochem. Pharmacol., 57, 727, 10.1016/S0006-2952(98)00307-4 Beranek, 1990, Distribution of methyl and ethyl adducts following alkylation with monofunctional alkylating agents, Mutat. Res., 231, 11, 10.1016/0027-5107(90)90173-2 Di, 2010, Influence of the phosphodiesterase-5 inhibitor, sildenafil, on sensitivity to chemotherapy in breast tumor cells, Breast Cancer Res. Treat., 124, 349, 10.1007/s10549-010-0765-7 Teleman, 2012, Automated selected reaction monitoring software for accurate label-free protein quantification, J. Proteome Res., 11, 3766, 10.1021/pr300256x Ostling, 1984, Microelectrophoretic study of radiation-induced DNA damages in individual mammalian cells, Biochem. Biophys. Res. Commun., 123, 291, 10.1016/0006-291X(84)90411-X Guler, 2011, Aberrant expression of DNA damage response proteins is associated with breast cancer subtype and clinical features, Breast Cancer Res. Treat., 129, 421, 10.1007/s10549-010-1248-6 Asakawa, 2010, Prediction of breast cancer sensitivity to neoadjuvant chemotherapy based on status of DNA damage repair proteins, Breast Cancer Res., 12, R17, 10.1186/bcr2486 O’Connor, 1997, Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents, Cancer Res., 57, 4285 Fan, 1994, p53 gene mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents, Cancer Res., 54, 5824 Millour, 2011, ATM and p53 regulate FOXM1 expression via E2F in breast cancer epirubicin treatment and resistance, Mol. Cancer Ther., 10, 1046, 10.1158/1535-7163.MCT-11-0024 Cersosimo, 1986, Epirubicin: a review of the pharmacology, clinical activity, and adverse effects of an adriamycin analogue, J. Clin. Oncol., 4, 425, 10.1200/JCO.1986.4.3.425 Leong, 2012, Biomarkers of breast cancer apoptosis induced by chemotherapy and TRAIL, J. Proteome Res., 11, 1240, 10.1021/pr200935y Chen, 2001, Relationship between base excision repair capacity and DNA alkylating agent sensitivity in mouse monocytes, Mutat. Res., 487, 121, 10.1016/S0921-8777(01)00110-0